(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/185733 A8

(51) International Patent Classification:
C07K 16/22 (2006.01) *A61P 35/00* (2006.01)
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/CN2025/081278

(22) International Filing Date:
07 March 2025 (07.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2024/080506
07 March 2024 (07.03.2024) CN
PCT/CN2024/096309
30 May 2024 (30.05.2024) CN
PCT/CN2024/096438
30 May 2024 (30.05.2024) CN
PCT/CN2024/112562
16 August 2024 (16.08.2024) CN
P240102655 30 September 2024 (30.09.2024) AR
PCT/CN2024/124994
15 October 2024 (15.10.2024) CN

(71) Applicants: **BIOTHEUS INC.** [CN/CN]; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **BIONTECH SE** [DE/DE]; An Der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: **HU, Guoqiang**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **LIU, Jing**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **ZHANG, Juan**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **OU, Yankui**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **DONG, Jie**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **SAHIN, Ugur**; An Der Goldgrube 12, 55131 Mainz (DE). **LI, Na**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN).

(74) Agent: **TEE & HOWE INTELLECTUAL PROPERTY ATTORNEYS**; Suite1,6-12, 5th Floor, Tower W1, The Tower Offices, Oriental Plaza, No.1 East Chang'an Avenue, Dongcheng District, Beijing 100738 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
02 October 2025 (02.10.2025)

(15) Information about Correction:
see Notice of 02 October 2025 (02.10.2025)

(54) Title: COMBINATION THERAPY COMPRISING A PD-1/PD-L1 AND VEGF/VEGFR BINDING AGENT AND A CHEMOTHERAPY FOR CANCER TREATMENT

(57) Abstract: The invention relates to a binding agent comprising (i) a first binding region which binds to PD-1, PD-L1, or both and which antagonizes the PD-1/PD-L1 interaction; and (ii) a second binding region which binds to VEGF, VEGF receptor (VEGFR), or both and which antagonizes the VEGF/VEGFR interaction (more particularly to a bispecific antibody that specifically binds to programmed death-ligand 1 (PD-L1) and Vascular Endothelial Growth Factor (VEGF)) for use in the treatment of a subject afflicted with cancer, wherein the subject is administered a combination comprising the binding agent (more particularly the bispecific antibody) and a chemotherapy, optionally wherein the subject has a PD-L1 expression before the treatment that provides a score of ≥1 when determined by the combined positive score (CPS) or a score that is indicative of such a PD-L1 expression when determined by another integrating scoring algorithm.

WO 2025/185733 A8